Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the On May 29, 2026, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $183 from $180 and maintained an Outperform rating on the shares.
RBC said the stock has rebounded after a strong Q1, though concerns remain that Crenessity uptake could hit a near-term ceiling
RBC also said its endocrinologist survey suggests room for near- and long-term growth, including expected utilization growth among doctors not currently using the drug. On May 21, 2026, Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) with an Outperform rating and a $221 price target. Walch described Neurocrine as one of the more promising names in Bernstein’s initial coverage group of mid-cap biopharmaceutical companies, noting that the company’s two key medicines are already approved and have a long runway until loss-of-exclusivity.
Bernstein added that upside could come as the market gains more certainty around future market share and a Phase 3 trial readout. create jobs 51/ Earlier in May, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported Q1 adjusted EPS of $1.94, ahead of the consensus estimate of $1.70. Revenue totaled $811M, above the consensus estimate of $767.88M. CEO Kyle Gano said the quarter reflected “continued momentum” across the commercial portfolio, with net product sales up 44% year-over-year, driven by demand for INGREZZA and CRENESSITY.